Skip to main content
. Author manuscript; available in PMC: 2019 Sep 15.
Published in final edited form as: Clin Cancer Res. 2018 May 30;24(18):4416–4428. doi: 10.1158/1078-0432.CCR-17-3649

Figure 6. Correlation of serum biomarkers with response to TIL ACT and anti-CTLA4 exposure.

Figure 6

(A–D) Grouped dot plot (left graph) and ROC curve (right graph) of the different time points in the serum of TIL treated patients. (A) Baseline serum level of circulating IL-9 comparing responders (R) from non-responders (NR) (n=50). Using recursive partitioning analysis, baseline IL-9 levels are predictive of response to TIL ACT. (B) Pre-IL-2 serum level of sTNF-R1 comparing responders (R) from non-responders (NR) (second round of IL-2, ~ 3 weeks post-TIL infusion) (n=48). (C) 3 month post-infusion level of sULBP-1 comparing responders (R) from non-responders (NR) (second round of IL-2, ~3 weeks post-TIL infusion) (n=39). (D) Baseline serum level of sMICB (n=41) and sCD25 (n=51) of patients exposed to anti-CTLA4 (YES) or not (NO) prior to TIL ACT. Number of patient in each groups varies depending on availably for either time point or marker panel.